Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna for $14bn and the subsequent FDA approval of Cobenfy, a novel schizophrenia drug, represents a significant strategic win. Cobenfy, the first new schizophrenia treatment in 35 years, has peak sales potential estimated at $7.5bn, validating Bristol-Myers' investment and boosting its market position. Despite recent financial struggles and high debt, Bristol-Myers' robust pipeline and strategic acquisitions position it for substantial revenue growth by 2030.
Pharma Stock Rises on Cleared Schizophrenia Treatment
Bristol-Myers Squibb Co (NYSE:BMY) is up 3.2% at $51.71, after the U.S. Food & Drug Administration (FDA) approved the pharma name's schizophrenia treatment, Cobenfy.
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
The FDA approves BMY's differentiated schizophrenia treatment for adults and broadens its diverse portfolio. Shares gain.
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Shares of Bristol Myers Squibb (BMY) rose Friday, a day after the Food and Drug Administration (FDA) approved the use of what the pharmaceutical firm called the first treatment for schizophrenia in decades.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Bristol Myers Squibb shares move higher on FDA approval of schizophrenia drug
Bristol Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) shares moved higher after the pharmaceutical company's schizophrenia drug was approved by the Food and Drug Administration (FDA), marking the first new treatment to be approved for the mental illness in decades. The company said its twice-daily pill, sold under the brand name COBENFY, will be available starting in October.
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
On Thursday, the FDA approved Bristol Myers Squibb & Co's BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
Bristol-Myers Squibb: Unlocking Value With KarXT FDA Approval And Oncology Pipeline Progress
Bristol-Myers Squibb is rated a "Buy" for long-term investors due to the revenue potential of KarXT (Cobenfy) and advancements in its oncology portfolio. Despite recent financial setbacks, BMY's strategic acquisitions and strong drug portfolio growth are poised to drive significant revenue from 2025 onwards. The Company offers a compelling dividend yield of nearly 5%, with a strong dividend growth rate, making it attractive for value investors.
Bristol Myers Stock Jumps. Why Approval for Its Schizophrenia Drug Is Ground Breaking.
The drug is one of an emerging class of drugs that has drawn the interest of large pharma companies.
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
Bristol Myers Squibb stock (NYSE: BMY) will be in focus in the near term after the U.S. FDA approved Cobenfy for the treatment of Schizophrenia. This is a big approval for the company, given that Cobenfy doesn't have the classic side effects seen in other antipsychotic drugs.
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia drug.
US drug regulator approves the first new schizophrenia drug in 30 years
The US Food and Drug Administration (FDA) has approved Cobenfy, the first new drug for schizophrenia in over 30 years, developed by Bristol Myers Squibb. Taken as a twice-daily pill, the treatment combines xanomeline and trospium chloride to manage common symptoms such as hallucinations and delusions.
